Intracellular Nucleotide Levels during Coadministration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1-Infected Patients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2011-01-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00910-10PMID 21282432PMCID PMC3067129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients

  2010cited by this paper
• Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.

  2009cited by this paper
• Conserved T cell and natural killer cell function in treatment‐experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone

  2009cited by this paper
• Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.

  2009cited by this paper
• The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals

  2009cited by this paper
• Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens

  2008cited by this paper
• Effect of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors of HIV on Endogenous Nucleotide Pools

  2008cited by this paper
• Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System

  2008cited by this paper
• Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood Cells

  2007cited by this paper
• Effect of Hydroxyurea and Dideoxyinosine on Intracellular 3′-Deoxyadenosine-5′-triphosphate Concentrations in HIV-Infected Patients

  2007cited by this paper
• Longitudinal Study on Mitochondrial Effects of Didanosine–Tenofovir Combination

  2006cited by this paper
• Short-Term Safety and Tolerability of Didanosine Combined with High- versus Low-Dose Tenofovir Disproxil Fumarate in Ambulatory HIV-1–Infected Persons

  2006cited by this paper
• Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy

  2006cited by this paper
• Higher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir

  2006cited by this paper
• In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells

  2006cited by this paper
• Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

  2005cited by this paper
• The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily

  2005cited by this paper
• Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir

  2005cited by this paper
• Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial

  2005cited by this paper
• Drug‐Drug and Drug‐Food Interactions Between Tenofovir Disoproxil Fumarate and Didanosine

  2005cited by this paper
• Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine

  2005cited by this paper
• Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz

  2005cited by this paper
• Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

  2005cited by this paper
• Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients

  2005influential reference
• Fanconi syndrome associated with didanosine therapy.

  2005cited by this paper
• Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens

  2005cited by this paper
• Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.

  2005cited by this paper
• CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.

  2004cited by this paper
• Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase

  2004cited by this paper
• Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load

  2004cited by this paper
• Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir

  2004cited by this paper
• Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.

  2004cited by this paper
• Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients

  2004cited by this paper
• Peripheral blood mononuclear cell counting using a DNA-detection-based method.

  2004cited by this paper
• K65R with and without S68: A New Resistance Profile in Vivo Detected in Most Patients Failing Abacavir, Didanosine and Stavudine

  2003cited by this paper
• Metabolism of Tenofovir and Didanosine in Quiescent or Stimulated Human Peripheral Blood Mononuclear Cells

  2003influential reference
• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine

  2003cited by this paper
• Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach

  2003cited by this paper
• Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

  2002cited by this paper
• Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.

  1997cited by this paper
• A NONCLINICAL SAFETY ASSESSMENT OF DIDANOSINE, A NUCLEOSIDE ANALOGUE WITH ANTI-HUMAN IMMUNODEFICIENCY VIRUS ACTIVITY

  1995cited by this paper
• A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent.

  1995cited by this paper
• Rates and risk factors for adverse events associated with didanosine in the expanded access program.

  1994cited by this paper

• Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV

  2021cites this paper
• Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection

  2020cites this paper
• Efficacy of oral tenofovir alafenamide/emtricitabine combination or single agent tenofovir alafenamide against vaginal SHIV infection in macaques.

  2019cites this paper
• Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus

  2018cites this paper
• Liquid chromatography–mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs

  2017cites this paper
• Development and validation of a LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate

  2017cites this paper
• Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.

  2017cites this paper
• Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate.

  2017cites this paper
• Bioanalysis and pharmacokinetics-pharmacodynamics modeling of the endogenous 2'deoxynucleoside triphosphate pool in individuals receiving tenofovir/emtricitabine

  2017influential citation
• Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates

  2016cites this paper
• Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine

  2016cites this paper
• Simultaneous determination of 2',3'-dideoxyinosine and the active metabolite, 2',3'-dideoxyadenosine-5'-triphosphate in human peripheral-blood mononuclear cell by HPLC-MS/MS and the application to cell pharmacokinetics.

  2015cites this paper
• Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry

  2015cites this paper
• Linking the Population Pharmacokinetics of Tenofovir and Its Metabolites With Its Cellular Uptake and Metabolism

  2014cites this paper
• Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.

  2013cites this paper
• Compared to Subcutaneous Tenofovir, Oral Tenofovir Disoproxyl Fumarate Administration Preferentially Concentrates the Drug into Gut-Associated Lymphoid Cells in Simian Immunodeficiency Virus-Infected Macaques

  2012influential citation
• Analysis of in vivo absorption of didanosine tablets in male adult dogs by HPLC

  2011cites this paper